|
Basic Characteristics of Mutations
|
|
Mutation Site
|
I195M |
|
Mutation Site Sentence
|
Because of overlapping open reading frames there are often HBsAg peptide changes that result from the emergence of polymerase drug resistant (DR) mutations, for instance, polymerase mutations M552V, M552I, A529V, T532G, and S550I result in the HBsAg alterations I195M, W196S, L173F, L176V, and V194F, respectively. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
-
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
21786803
|
|
Title
|
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion
|
|
Author
|
Yu W,Goddard C,Clearfield E,Mills C,Xiao T,Guo H,Morrey JD,Motter NE,Zhao K,Block TM,Cuconati A,Xu X
|
|
Journal
|
Journal of medicinal chemistry
|
|
Journal Info
|
2011 Aug 25;54(16):5660-70
|
|
Abstract
|
The high levels of hepatitis B virus (HBV) surface antigen (HBsAg)-bearing subviral particles in the serum of chronically infected individuals play an important role in suppressing HBV-specific immune response and are only mildly affected by the current small molecule therapies. Thus, a therapy that specifically reduces HBsAg serum levels could be used in combination therapy with nucleos(t)ide drugs or permit therapeutic vaccination for the treatment of HBV infection. Herein, we report the design, synthesis, and evaluation of novel triazolo-pyrimidine inhibitors (1, 3, and 4) of HBsAg cellular secretion, with activity against drug-resistant HBV variants. Extensive SAR led to substantial improvements in the EC(50) of the parent compound, 5 (HBF-0259), with the best being 3c, with EC(50) = 1.4 +/- 0.4 muM, SI >/= 36. The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats.
|
|
Sequence Data
|
-
|
|
|